Literature DB >> 19889140

Hepatitis A virus (HAV) proteinase 3C inhibits HAV IRES-dependent translation and cleaves the polypyrimidine tract-binding protein.

T Kanda1, V Gauss-Müller, S Cordes, R Tamura, K Okitsu, W Shuang, S Nakamoto, K Fujiwara, F Imazeki, O Yokosuka.   

Abstract

Hepatitis A virus (HAV) infection is still an important issue worldwide. A distinct set of viruses encode proteins that enhance viral cap-independent translation initiation driven by an internal ribosome entry site (IRES) and suppress cap-dependent host translation. Unlike cytolytic picornaviruses, replication of HAV does not cause host cell shut off, and it has been questioned whether HAV proteins interfere with its own and/or host translation. HAV proteins were coexpressed in Huh-7 cells with reporter genes whose translation was initiated by either cap-dependent or cap-independent mechanisms. Among the proteins tested, HAV proteinase 3C suppressed viral IRES-dependent translation. Furthermore, 3C cleaved the polypyrimidine tract-binding protein (PTB) whose interaction with the HAV IRES had been demonstrated previously. The combined results suggest that 3C-mediated cleavage of PTB might be involved in down-regulation of viral translation to give way to subsequent viral genome replication.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19889140     DOI: 10.1111/j.1365-2893.2009.01221.x

Source DB:  PubMed          Journal:  J Viral Hepat        ISSN: 1352-0504            Impact factor:   3.728


  15 in total

1.  Hepatitis A Virus Infection and Molecular Research.

Authors:  Tatsuo Kanda; Reina Sasaki-Tanaka; Shingo Nakamoto
Journal:  Int J Mol Sci       Date:  2022-06-29       Impact factor: 6.208

2.  Interactions between PTB RRMs induce slow motions and increase RNA binding affinity.

Authors:  Caroline M Maynard; Kathleen B Hall
Journal:  J Mol Biol       Date:  2010-01-18       Impact factor: 5.469

3.  Inhibitory effects on HAV IRES-mediated translation and replication by a combination of amantadine and interferon-alpha.

Authors:  Lingli Yang; Tomoko Kiyohara; Tatsuo Kanda; Fumio Imazeki; Keiichi Fujiwara; Verena Gauss-Müller; Koji Ishii; Takaji Wakita; Osamu Yokosuka
Journal:  Virol J       Date:  2010-09-03       Impact factor: 4.099

4.  Translation directed by hepatitis A virus IRES in the absence of active eIF4F complex and eIF2.

Authors:  Natalia Redondo; Miguel Angel Sanz; Jutta Steinberger; Tim Skern; Yuri Kusov; Luis Carrasco
Journal:  PLoS One       Date:  2012-12-18       Impact factor: 3.240

5.  Analysis of 5' nontranslated region of hepatitis A viral RNA genotype I from South Korea: comparison with disease severities.

Authors:  Tatsuo Kanda; Sook-Hyang Jeong; Fumio Imazeki; Keiichi Fujiwara; Osamu Yokosuka
Journal:  PLoS One       Date:  2010-12-28       Impact factor: 3.240

Review 6.  Nuclear proteins hijacked by mammalian cytoplasmic plus strand RNA viruses.

Authors:  Richard E Lloyd
Journal:  Virology       Date:  2015-03-26       Impact factor: 3.616

Review 7.  Picornaviruses and nuclear functions: targeting a cellular compartment distinct from the replication site of a positive-strand RNA virus.

Authors:  Dylan Flather; Bert L Semler
Journal:  Front Microbiol       Date:  2015-06-18       Impact factor: 5.640

Review 8.  Direct-acting Antivirals and Host-targeting Agents against the Hepatitis A Virus.

Authors:  Tatsuo Kanda; Shingo Nakamoto; Shuang Wu; Masato Nakamura; Xia Jiang; Yuki Haga; Reina Sasaki; Osamu Yokosuka
Journal:  J Clin Transl Hepatol       Date:  2015-09-15

Review 9.  New insights into functional roles of the polypyrimidine tract-binding protein.

Authors:  Maria Grazia Romanelli; Erica Diani; Patricia Marie-Jeanne Lievens
Journal:  Int J Mol Sci       Date:  2013-11-20       Impact factor: 5.923

10.  Suppression of La antigen exerts potential antiviral effects against hepatitis A virus.

Authors:  Xia Jiang; Tatsuo Kanda; Shuang Wu; Shingo Nakamoto; Kengo Saito; Hiroshi Shirasawa; Tomoko Kiyohara; Koji Ishii; Takaji Wakita; Hiroaki Okamoto; Osamu Yokosuka
Journal:  PLoS One       Date:  2014-07-07       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.